---
title: "Pharyngitis and Tonsillitis"
order: 4
category: "Otolaryngology"
---

# Pharyngitis and Tonsillitis

## Overview

Pharyngitis, inflammation of the pharynx, and tonsillitis, inflammation of the palatine tonsils, are among the most common reasons for outpatient visits, particularly in children and young adults. Acute pharyngitis accounts for over 12 million office visits annually in the United States. The vast majority of cases (70-90%) are viral and self-limited, but bacterial pharyngitis, particularly Group A Streptococcus (GAS), requires appropriate antibiotic therapy to prevent suppurative and non-suppurative complications. Understanding the clinical differentiation between viral and bacterial causes, appropriate use of diagnostic testing, evidence-based antibiotic therapy, and recognition of complications including peritonsillar abscess is essential for all clinicians.

### Epidemiology
- **Incidence**: 11 million annual office visits in the US
- **Age distribution**: Peak in children 5-15 years (GAS pharyngitis)
- **Seasonal variation**: Late fall through early spring for GAS
- **Viral**: More common in all age groups
- **Bacterial (GAS)**: 20-30% of pharyngitis in children, 5-15% in adults
- **Economic burden**: Significant costs from visits, testing, antibiotics, missed work/school

### Classification
- **By etiology**: Viral, bacterial, fungal, non-infectious
- **By location**: Pharyngitis (diffuse), tonsillitis (localized to tonsils), pharyngotonsillitis (both)
- **By duration**: Acute (<3 weeks), chronic (>3 weeks)
- **By severity**: Uncomplicated, complicated (abscess, cellulitis)

## Anatomy

### Pharynx

#### Divisions
- **Nasopharynx**: Above soft palate, contains adenoids
- **Oropharynx**: Soft palate to epiglottis, contains palatine tonsils
- **Hypopharynx/Laryngopharynx**: Epiglottis to cricopharyngeus

#### Oropharynx (Primary Site)
- **Boundaries**: Soft palate (superior), base of tongue (inferior), tonsillar pillars (lateral)
- **Contents**: Palatine tonsils, posterior pharyngeal wall, base of tongue
- **Waldeyer's ring**: Lymphoid tissue (palatine tonsils, adenoids, lingual tonsils, pharyngeal bands)

### Palatine Tonsils

#### Structure
- **Location**: Between anterior (palatoglossus) and posterior (palatopharyngeus) tonsillar pillars
- **Lymphoid tissue**: Organized follicles with germinal centers
- **Crypts**: 10-30 deep invaginations, increase surface area
- **Capsule**: Separates tonsil from pharyngeal constrictor muscle

#### Function
- **Immune surveillance**: First-line defense, sample antigens
- **B-cell activation**: Antibody production
- **T-cell maturation**: Cellular immunity
- **Peak size**: Age 4-7 years, then gradual involution
- **Not essential**: Tonsillectomy does not impair immune function

#### Blood Supply
- **Tonsillar branch** of facial artery (primary)
- **Ascending pharyngeal artery**
- **Ascending and descending palatine arteries**
- **Dorsal lingual artery**

## Acute Viral Pharyngitis

### Etiology

#### Common Viral Pathogens
- **Rhinovirus**: 20% of pharyngitis
- **Coronavirus**: 5-10%
- **Adenovirus**: 5%, can cause exudative pharyngitis mimicking GAS
- **Influenza A & B**: Seasonal
- **Parainfluenza**: Croup association
- **Respiratory syncytial virus (RSV)**: Especially children
- **Herpes simplex virus (HSV)**: Gingivostomatitis (HSV-1), genital (HSV-2)
- **Epstein-Barr virus (EBV)**: Infectious mononucleosis
- **Cytomegalovirus (CMV)**: Mononucleosis-like syndrome
- **HIV**: Acute retroviral syndrome

### Clinical Presentation

#### Typical Viral Features
- **Gradual onset**: Over 1-2 days
- **Conjunctivitis**: Adenovirus (pharyngoconjunctival fever)
- **Coryza**: Runny nose
- **Cough**: Common
- **Hoarseness**: Laryngeal involvement
- **Diarrhea**: Especially enteroviruses
- **Low-grade fever**: <38.3°C (101°F), if present
- **Oral ulcers**: Aphthous, herpetic
- **Exanthem**: Various viral rashes

#### Specific Viral Syndromes

**Infectious mononucleosis (EBV):**
- **Triad**: Fever, pharyngitis, lymphadenopathy
- **Exudative tonsillitis**: Thick, white exudates
- **Posterior cervical lymphadenopathy**: Characteristic
- **Splenomegaly**: 50%, peak week 2-3
- **Hepatomegaly**: 10-15%
- **Rash**: 5-15% spontaneously, 90% if given ampicillin (not true allergy)
- **Palatal petechiae**: At junction of hard and soft palate
- **Fatigue**: Profound, prolonged (weeks to months)

**Herpangina (Coxsackie A):**
- **Small vesicles/ulcers**: Posterior pharynx, soft palate, uvula
- **High fever**: Sudden onset
- **Odynophagia**: Painful swallowing
- **Preschool age**: Typically young children

**Hand-foot-mouth disease (Coxsackie A16, Enterovirus 71):**
- **Oral ulcers**: Buccal mucosa, tongue, palate (less posterior than herpangina)
- **Rash**: Vesicular on palms, soles, buttocks
- **Age**: Young children

**Herpetic gingivostomatitis (HSV-1):**
- **Vesicles/ulcers**: Gingiva, lips, anterior mouth
- **Severe pain**: Difficulty eating/drinking
- **Fever**: High
- **Lymphadenopathy**: Anterior cervical
- **Primary infection**: Usually children, can be adults

### Diagnosis
- **Clinical**: Based on features above
- **Testing not routinely indicated**: Self-limited
- **EBV testing**: If classic mono presentation
  - **Monospot/heterophile antibody**: Positive after 1 week, sensitivity 85%
  - **EBV-specific serology**: If monospot negative but high suspicion (IgM VCA positive in acute)
  - **CBC**: Lymphocytosis, atypical lymphocytes (>10%)

### Treatment
- **Supportive**: Analgesics, antipyretics, hydration, rest
- **No antibiotics**: Unless bacterial superinfection
- **NSAIDs/acetaminophen**: Pain and fever
- **Topical anesthetics**: Viscous lidocaine, benzocaine sprays (limited benefit, aspiration risk)
- **Avoid aspirin**: Especially children (Reye syndrome risk)
- **Infectious mono**: Avoid contact sports for 3-4 weeks (splenic rupture risk), avoid ampicillin (rash)

## Acute Bacterial Pharyngitis

### Group A Streptococcus (GAS, S. pyogenes)

#### Epidemiology
- **Most important bacterial cause**: 20-30% in children, 5-15% in adults
- **Age**: Peak 5-15 years, rare <3 years and in adults
- **Transmission**: Respiratory droplets, close contact
- **Incubation**: 2-5 days
- **Communicability**: Untreated - weeks; treated - 24 hours after antibiotic initiation

#### Pathophysiology
- **M protein**: Major virulence factor, >100 serotypes
- **Streptococcal pyrogenic exotoxins**: Superantigens (scarlet fever, TSS)
- **Streptolysin O and S**: Hemolysins
- **Hyaluronidase, DNase**: Spread through tissues
- **Immune-mediated complications**: Molecular mimicry (rheumatic fever), immune complex (glomerulonephritis)

#### Clinical Presentation

**Typical features:**
- **Sudden onset**: Acute sore throat
- **Odynophagia**: Painful swallowing
- **Fever**: ≥38°C (100.4°F), often higher
- **Tonsillopharyngeal erythema**: Bright red
- **Tonsillar exudates**: White/yellow patches (50%)
- **Palatal petechiae**: Small red spots on soft palate
- **Anterior cervical lymphadenopathy**: Tender, enlarged nodes
- **Headache, abdominal pain**: Especially children
- **Absence of cough, rhinorrhea, conjunctivitis**: Helps distinguish from viral

**Scarlet fever:**
- **Sandpaper rash**: Erythematous, blanching, fine papular
- **Distribution**: Trunk, extremities; spares palms, soles, face
- **Pastia lines**: Accentuation in skin folds
- **Strawberry tongue**: Initially white-coated with prominent papillae, then beefy red
- **Desquamation**: Hands and feet after 1-2 weeks
- **Treatment**: Same as GAS pharyngitis

#### Modified Centor Score (Adults)

**Criteria (1 point each):**
1. Tonsillar exudates
2. Tender anterior cervical lymphadenopathy
3. Fever (history or >38°C)
4. Absence of cough

**Age modification:**
- Age 3-14 years: +1 point
- Age 15-44 years: 0 points
- Age ≥45 years: -1 point

**Interpretation and management:**
- **Score 0-1**: 1-10% GAS probability - no testing, no antibiotics
- **Score 2-3**: 11-35% probability - test, treat if positive
- **Score 4-5**: 51-53% probability - consider empiric treatment OR test and treat if positive

**Limitations:**
- Validated in adults, less reliable in children
- Regional GAS prevalence varies
- Clinical gestalt also important

#### Diagnosis

**Rapid Antigen Detection Test (RADT):**
- **Sensitivity**: 70-90%
- **Specificity**: 95%
- **Time**: 5-10 minutes
- **Positive result**: Treat (high specificity)
- **Negative result in children/adolescents**: Confirm with culture (lower sensitivity)
- **Negative result in adults**: No culture needed (lower pretest probability, higher negative predictive value)

**Throat culture:**
- **Gold standard**: Sensitivity 90-95%
- **Time**: 24-48 hours
- **Indications**:
  - Negative RADT in children/adolescents with high clinical suspicion
  - Epidemiologic surveillance
  - Suspected treatment failure

**Molecular testing (PCR):**
- **Sensitivity**: >95%
- **Specificity**: 95%
- **Time**: 1-2 hours
- **Increasing availability**: May replace RADT+culture
- **Cannot distinguish**: Active infection vs carrier state

**Culture technique:**
- **Vigorous swabbing**: Both tonsils and posterior pharynx
- **Avoid**: Tongue, teeth, buccal mucosa (normal flora contamination)

**ASO titer, anti-DNase B:**
- **Not useful** for acute diagnosis
- **Used**: Retrospectively for post-streptococcal complications (ARF, PSGN)

#### Treatment

**Goals:**
- Prevent suppurative complications (peritonsillar abscess, cervical lymphadenitis)
- Prevent acute rheumatic fever
- Shorten duration of symptoms (modest, ~1 day)
- Reduce transmission
- Note: Antibiotics do NOT prevent post-streptococcal glomerulonephritis

**First-line: Penicillin**
- **Penicillin VK**: 500 mg PO BID-TID × 10 days (adults); 250 mg BID-TID × 10 days (children <27 kg)
- **Benzathine penicillin G**: 1.2 million units IM once (adults/children ≥27 kg); 600,000 units IM once (children <27 kg)
  - **Advantage**: Single dose, ensures compliance
  - **Disadvantage**: Painful injection
- **Rationale**: Narrow spectrum, inexpensive, no GAS resistance to penicillin

**Alternative: Amoxicillin**
- **Dose**: 50 mg/kg once daily (max 1000 mg) OR 25 mg/kg BID (max 500 mg per dose) × 10 days
- **Advantage**: Better taste (children), once-daily option, FDA-approved
- **Broader spectrum**: Treats concurrent otitis media if present

**Penicillin allergy:**

**Non-anaphylactic:**
- **Cephalexin**: 500 mg BID × 10 days (adults)
- **Cefadroxil**: 1 g once daily × 10 days
- **Note**: Cross-reactivity <1% for non-anaphylactic PCN allergy

**Anaphylactic (type I hypersensitivity):**
- **Azithromycin**: 12 mg/kg once daily (max 500 mg) × 5 days
  - **Concern**: 5-10% macrolide resistance in some areas
- **Clarithromycin**: 250 mg BID × 10 days
- **Clindamycin**: 300 mg TID × 10 days
  - **Most effective alternative**: Low resistance

**Duration:**
- **10 days**: Required for penicillin, amoxicillin, cephalosporins (prevent ARF)
- **5 days**: Azithromycin (adequate due to prolonged tissue levels)
- **Shorter courses**: NOT recommended for beta-lactams (ARF prevention requires 10 days)

**Symptom relief:**
- **Analgesics**: NSAIDs or acetaminophen
- **Throat lozenges**: Modest symptomatic benefit
- **Saltwater gargles**: May soothe
- **Corticosteroids**: Single dose may hasten symptom relief (controversial, not routinely recommended)

#### Complications

**Suppurative (local):**
- **Peritonsillar abscess**: Most common (see below)
- **Retropharyngeal abscess**: Deep neck space infection
- **Parapharyngeal abscess**: Lateral pharyngeal space
- **Cervical lymphadenitis**: Suppurative nodes
- **Otitis media, sinusitis**: Contiguous spread
- **Mastoiditis**: Rare

**Non-suppurative (immune-mediated):**

**Acute rheumatic fever (ARF):**
- **Pathophysiology**: Molecular mimicry between GAS M protein and cardiac myosin
- **Latency**: 2-3 weeks after pharyngitis
- **Jones criteria**: Diagnosis requires 2 major OR 1 major + 2 minor criteria plus evidence of preceding GAS
- **Major criteria**: Carditis, polyarthritis, chorea, erythema marginatum, subcutaneous nodules
- **Minor criteria**: Fever, arthralgia, elevated ESR/CRP, prolonged PR interval
- **Most serious**: Carditis (valvular damage, especially mitral)
- **Prevention**: Timely antibiotic treatment within 9 days of symptom onset
- **Secondary prophylaxis**: Long-term penicillin for those with ARF history

**Post-streptococcal glomerulonephritis (PSGN):**
- **Pathophysiology**: Immune complex deposition in glomeruli
- **Latency**: 1-3 weeks (pharyngitis) or 3-6 weeks (skin infection)
- **Presentation**: Hematuria, edema, hypertension, oliguria
- **Lab**: Elevated ASO/anti-DNase B, low C3 complement, RBC casts
- **Prevention**: Antibiotics do NOT prevent PSGN
- **Treatment**: Supportive (fluid restriction, antihypertensives)
- **Prognosis**: Excellent in children (>95% complete recovery)

**Streptococcal toxic shock syndrome:**
- **Rare**: Severe invasive GAS infection
- **Presentation**: Hypotension, multi-organ failure, rash
- **Treatment**: ICU, IV antibiotics (penicillin + clindamycin), supportive care
- **Mortality**: 30-50%

**PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections):**
- **Controversial**: Proposed link between GAS and OCD/tics
- **Evidence**: Limited, mechanism uncertain
- **Not routinely treated**: With antibiotic prophylaxis

### Other Bacterial Causes (Less Common)

#### Group C and G Streptococci
- **Clinical**: Similar to GAS
- **Complications**: Rarely cause ARF or PSGN
- **Treatment**: Same as GAS

#### Fusobacterium necrophorum
- **Lemierre syndrome**: Rare but serious
- **Presentation**: Severe pharyngitis → internal jugular vein thrombophlebitis → septic emboli
- **Diagnosis**: Blood cultures, imaging (CT with contrast showing IJV thrombus)
- **Treatment**: Prolonged IV antibiotics (penicillin + metronidazole or clindamycin), anticoagulation controversial

#### Neisseria gonorrhoeae
- **Risk**: Sexual contact (oral sex)
- **Presentation**: Usually asymptomatic or mild pharyngitis
- **Diagnosis**: NAAT or culture
- **Treatment**: Ceftriaxone 500 mg IM × 1 (if <150 kg)

#### Corynebacterium diphtheriae
- **Rare in vaccinated populations**: Toxin-mediated disease
- **Presentation**: Adherent gray pseudomembrane, "bull neck" lymphadenopathy
- **Treatment**: Antitoxin + antibiotics (penicillin or erythromycin), isolation

## Peritonsillar Abscess (PTA, Quinsy)

### Pathophysiology
- **Progression**: Acute tonsillitis → peritonsillar cellulitis → abscess formation
- **Location**: Between tonsillar capsule and superior pharyngeal constrictor muscle
- **Polymicrobial**: GAS, oral anaerobes (Fusobacterium, Prevotella, Peptostreptococcus)

### Epidemiology
- **Incidence**: 30 per 100,000
- **Age**: Adolescents and young adults (15-30 years)
- **Risk factors**: Recurrent tonsillitis, smoking, GERD, periodontal disease

### Clinical Presentation

#### Symptoms
- **Severe sore throat**: Unilateral, progressive
- **Odynophagia**: Extreme difficulty swallowing
- **Trismus**: Difficulty opening mouth (30-50%)
- **Dysphagia**: Drooling
- **"Hot potato" voice**: Muffled, pharyngeal fullness
- **Otalgia**: Referred ear pain (ipsilateral)
- **Fever**: High-grade

#### Signs
- **Uvular deviation**: Away from affected side (classic finding)
- **Peritonsillar swelling**: Unilateral bulge, superior and medial displacement of tonsil
- **Erythema**: Overlying soft palate
- **Cervical lymphadenopathy**: Ipsilateral, tender
- **Asymmetric tonsillar enlargement**: Affected side larger
- **Fluctuance**: May be palpable (if abscess formed)

### Diagnosis
- **Clinical**: Based on history and examination
- **Needle aspiration**: Diagnostic and therapeutic
  - **Technique**: 18-gauge needle, aspirate at point of maximum fluctuance
  - **Positive**: Pus confirms diagnosis
  - **Send**: Gram stain, culture
- **Imaging** (not routinely needed):
  - **CT neck with contrast**: If diagnosis uncertain, concern for deep space extension, failed drainage
  - **Findings**: Ring-enhancing fluid collection, mass effect, parapharyngeal involvement

### Differential Diagnosis
- **Peritonsillar cellulitis**: No abscess formed, antibiotics alone may suffice
- **Retropharyngeal abscess**: More posterior, may have less trismus
- **Parapharyngeal abscess**: Lateral neck involvement
- **Infectious mononucleosis**: Bilateral tonsillar swelling, can have marked asymmetry
- **Lymphoma**: Painless, firm mass
- **Internal carotid artery aneurysm**: Rare, pulsatile (do not aspirate!)

### Treatment

#### Drainage (Essential)
- **Needle aspiration**: First-line, can be done in office/ED
  - **Success rate**: 85-95%
  - **Repeat**: If inadequate initial drainage
- **Incision and drainage**: If needle aspiration fails or recurrent
  - **Technique**: Incise at point of maximum fluctuance, blunt dissection to break loculations
- **Tonsillectomy (quinsy tonsillectomy)**: Immediate or interval
  - **Indications**: Failed drainage, recurrent PTA, unable to exclude malignancy

#### Antibiotics
- **Empiric**: Broad-spectrum, cover GAS and anaerobes
- **Outpatient** (mild, after drainage):
  - Amoxicillin-clavulanate 875/125 mg BID × 10 days
  - Clindamycin 300-450 mg TID × 10 days (if PCN allergic)
- **Inpatient** (severe, toxic, failed outpatient):
  - Ampicillin-sulbactam 3 g IV q6h
  - Clindamycin 600-900 mg IV q8h ± penicillin G
  - Piperacillin-tazobactam (alternative)

#### Adjunctive Management
- **Analgesics**: NSAIDs, opioids if severe
- **Corticosteroids**: Dexamethasone 10 mg IV/IM × 1 may reduce pain, hasten recovery (common practice, limited evidence)
- **Hydration**: IV fluids if unable to tolerate PO
- **Airway monitoring**: Rare airway compromise, but monitor

#### Disposition
- **Outpatient**: If able to swallow, reliable, adequate drainage, no airway concern, close follow-up
- **Inpatient**: Trismus, unable to swallow, airway concern, toxic appearance, failed outpatient therapy

### Complications (Rare)
- **Deep neck space infection**: Parapharyngeal, retropharyngeal extension
- **Airway obstruction**: From mass effect
- **Aspiration**: From drooling, dysphagia
- **Jugular vein thrombophlebitis**: Lemierre syndrome
- **Mediastinitis**: Descending infection
- **Carotid artery erosion**: Extremely rare

### Recurrence and Tonsillectomy
- **Recurrence rate**: 10-15% after first episode
- **Interval tonsillectomy** (elective, 4-6 weeks later):
  - **Indications**: Recurrent PTA, recurrent tonsillitis, cannot exclude malignancy
  - **Advantages**: Lower recurrence risk, addresses underlying pathology
  - **Disadvantages**: Two procedures, recovery time
- **Immediate (quinsy) tonsillectomy**:
  - **Performed at time of presentation**: Rarely done in US
  - **Higher bleeding risk**: More inflammation

## Chronic Tonsillitis

### Definition
Persistent tonsillar inflammation, usually from recurrent acute episodes.

### Clinical Features
- **Halitosis**: Chronic bad breath
- **Tonsillar hypertrophy**: Enlarged tonsils
- **Tonsilloliths**: White/yellow debris in crypts (keratin, bacteria, food)
- **Sore throat**: Chronic or recurrent
- **Cervical lymphadenopathy**: Persistent

### Management
- **Conservative**: Oral hygiene, saltwater gargles, manual expression of tonsilloliths
- **Tonsillectomy**: If meeting criteria (see below)

## Indications for Tonsillectomy

### AAO-HNS Clinical Practice Guideline (2019)

#### Paradise Criteria (Recurrent Throat Infection)
**Absolute indication:**
≥7 episodes in 1 year, OR
≥5 episodes per year for 2 years, OR
≥3 episodes per year for 3 years

**Documentation required for each episode:**
- Sore throat PLUS at least 1 of:
  - Temperature >38.3°C (101°F)
  - Cervical lymphadenopathy
  - Tonsillar exudate
  - Positive GAS test

#### Other Indications
- **Recurrent peritonsillar abscess**: After first episode (controversial) or second episode (generally accepted)
- **Obstructive sleep apnea**: Tonsillar hypertrophy causing OSA
- **Dysphagia**: Severe, affecting nutrition
- **Chronic tonsillitis**: Persistent despite medical management
- **Suspected malignancy**: Asymmetric tonsillar enlargement, firm, fixed

### Procedure
- **General anesthesia**: Required
- **Techniques**: Electrocautery, cold knife (steel), coblation, harmonic scalpel
- **Intracapsular vs extracapsular**: Extracapsular removes entire tonsil including capsule (standard)

### Outcomes
- **Symptom reduction**: Significant improvement in recurrent infections, sleep apnea
- **Quality of life**: Improved in appropriately selected patients
- **Not always curative**: Some still have pharyngitis (other causes)

### Complications
- **Pain**: Severe, days 3-5, improved by day 10-14
- **Hemorrhage**:
  - **Primary** (intraoperative or <24 hours): 0.5-1%
  - **Secondary** (days 5-10): 2-4%, from sloughing of eschar
  - **Management**: Return to OR for control if significant
- **Dehydration**: From odynophagia
- **Aspiration**: During or after surgery (rare)
- **Velopharyngeal insufficiency**: Nasal speech, nasal regurgitation (rare)
- **Infection**: Rare
- **Dental trauma**: From mouth gag
- **Death**: Extremely rare (1 in 15,000-20,000)

### Postoperative Care
- **Analgesia**: Scheduled acetaminophen, ibuprofen; opioids if needed (caution in OSA patients)
- **Hydration**: Push fluids, ice chips, popsicles
- **Diet**: Cold, soft foods; avoid acidic, spicy, rough foods
- **Activity**: Limit strenuous activity for 2 weeks (bleeding risk)
- **Warning signs**: Bright red blood (return immediately)
- **Follow-up**: 2-3 weeks postop

## Summary

Pharyngitis and tonsillitis are extremely common, predominantly viral, and self-limited. The primary clinical challenge is identifying bacterial pharyngitis, particularly Group A Streptococcus, which accounts for 20-30% of pediatric and 5-15% of adult cases. The Centor criteria help risk-stratify adults, guiding testing and treatment decisions. Rapid antigen detection testing or throat culture confirms GAS, with penicillin remaining first-line therapy for 10 days to prevent acute rheumatic fever. Most cases improve with supportive care, but complications include peritonsillar abscess (requiring drainage and antibiotics), acute rheumatic fever, and post-streptococcal glomerulonephritis. Peritonsillar abscess presents with severe unilateral sore throat, uvular deviation, and trismus, managed with needle aspiration or incision and drainage plus antibiotics. Tonsillectomy is indicated for recurrent throat infections meeting Paradise criteria, recurrent peritonsillar abscess, or obstructive sleep apnea. Understanding appropriate diagnosis, antibiotic stewardship, and recognition of complications ensures optimal management of pharyngitis and tonsillitis.
